Seeman P, Tallerico T
Department of Pharmacology, University of Toronto, Canada.
Mol Psychiatry. 1998 Mar;3(2):123-34. doi: 10.1038/sj.mp.4000336.
This review addresses two questions. First, why does clozapine apparently occupy low levels of dopamine D2 receptors in patients, in contrast to all other antipsychotic drugs which occupy 70-80% of brain dopamine D2 receptors? Second, what is the receptor basis of action of antipsychotic drugs which elicit low levels of Parkinsonism? Antipsychotic doses of clozapine occupy between 0% and 50% of D2 receptors, as measured in patients by a variety of radioligands. It has recently been found, however, that the percent occupancy of a receptor by a drug depends on the radioligand used to measure that receptor. Based on this new finding, this review concludes that clozapine clinically occupies high levels of D2 receptors in the absence of any radioligand. This occupancy is estimated to be of the order of 70-80% in the dopamine-rich region of the human striatum, and even higher in the limbic D2-containing regions which are low in endogenous synaptic dopamine. This conclusion arises from two different approaches. One approach is to relate the reported clozapine occupancies in the human striatum with the dissociation constants of the various radioligands at the D2 receptor. This relation extrapolates to approximately 70-80% occupancy by clozapine when clozapine competes with endogenous dopamine at the D2 receptor. The second approach is to calculate the D2 occupancy of each antipsychotic drug, using the average spinal fluid concentration and the correct dissociation constant of the antipsychotic, thereby revealing that all antipsychotic drugs, including clozapine, occupy approximately 70-80% of dopamine D2 receptors in the human striatum, and possibly higher in the limbic regions. As determined by the new dissociation constants, antipsychotic drugs which elicit Parkinsonism (trifluperazine, chlorpromazine, raclopride, haloperidol, fluphenazine, risperidone) bind more tightly than dopamine to D2, while those antipsychotic drugs which elicit little or no Parkinsonism (melperone, seroquel, perlapine, clozapine, remoxipride, molindone, sulpiride, olanzapine, sertindole) bind more loosely than dopamine to D2 receptors. Compared to the tightly bound antipsychotic drugs, the more loosely bound antipsychotics generally require higher clinical doses, require fewer days for clinical adjustment, but may dissociate from the D2 receptor more rapidly and could lead to clinical relapse somewhat earlier than that found with the traditional tightly bound antipsychotic drugs.
本综述探讨两个问题。其一,与所有其他占据脑内70 - 80%多巴胺D2受体的抗精神病药物相比,为何氯氮平在患者体内对多巴胺D2受体的占据水平明显较低?其二,引发低水平帕金森症的抗精神病药物的作用受体基础是什么?通过多种放射性配体测定,氯氮平的抗精神病剂量占据D2受体的0%至50%。然而,最近发现,药物对受体的占据百分比取决于用于测量该受体的放射性配体。基于这一新发现,本综述得出结论,在不存在任何放射性配体的情况下,氯氮平在临床上占据高水平的D2受体。据估计,在人类纹状体富含多巴胺的区域,这种占据率约为70 - 80%,而在含D2的边缘区域,由于内源性突触多巴胺水平较低,占据率甚至更高。这一结论源于两种不同的方法。一种方法是将报道的氯氮平在人类纹状体中的占据情况与各种放射性配体在D2受体处的解离常数相关联。当氯氮平在D2受体处与内源性多巴胺竞争时,这种关系外推得出氯氮平的占据率约为70 - 80%。第二种方法是利用抗精神病药物的平均脑脊液浓度和正确的解离常数来计算每种抗精神病药物的D2占据率,从而揭示所有抗精神病药物,包括氯氮平,在人类纹状体中占据约70 - 80%的多巴胺D2受体,在边缘区域可能更高。根据新的解离常数确定,引发帕金森症的抗精神病药物(三氟拉嗪、氯丙嗪、雷氯必利、氟哌啶醇、氟奋乃静、利培酮)与多巴胺相比,与D2的结合更紧密,而那些引发很少或不引发帕金森症的抗精神病药物(美哌隆、喹硫平、哌拉平、氯氮平、瑞莫必利、吗茚酮、舒必利、奥氮平、舍吲哚)与多巴胺相比,与D2受体的结合更松散。与结合紧密的抗精神病药物相比,结合较松散的抗精神病药物通常需要更高的临床剂量,临床调整所需天数更少,但可能从D2受体解离得更快,并且可能比传统的结合紧密的抗精神病药物更早导致临床复发。